mrjСовременная ревматологияModern Rheumatology Journal1996-70122310-158XIMA-PRESS, LLC10.14412/1996-7012-2022-1-7-13mrj-1245Research ArticleЛЕКЦИЯLECTUREИнгибиторы Янус-киназ в терапии псориатического артритаJanus kinase inhibitors in the treatment of psoriatic arthritishttps://orcid.org/0000-0001-6875-4552ЛогиноваЕ. Ю.LoginovaE. Yu.

Елена Юрьевна Логинова

115522, Москва, Каширское шоссе, 34А

Elena Yurievna Loginova

34A, Kashirskoe shosse, Moscow 115522

eyloginova@mail.ruhttps://orcid.org/0000-0003-0579-1131КоротаеваТ. В.KorotaevaT. V.

115522, Москва, Каширское шоссе, 34А

34A, Kashirskoe shosse, Moscow 115522

ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»РоссияV.A. Nasonova Research Institute of RheumatologyRussian Federation202217022022161713Copyright © Логинова Е.Ю., Коротаева Т.В., 20222022Логинова Е.Ю., Коротаева Т.В.Loginova E.Y., Korotaeva T.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://mrj.ima-press.net/mrj/article/view/1245

В статье представлен анализ данных литературы о применении новой группы таргетных синтетических базисных противовоспалительных препаратов (БПВП) ингибиторов Янус-киназ (Janus kinase, JAK) – тофацитиниба (ТОФА) и упадацитиниба (УПА) – при псориатическом артрите (ПсА). Результаты проведенных рандомизированных плацебоконтролируемых клинических исследованиий и длительных наблюдательных исследований свидетельствуют о высокой эффективности и безопасности использования ТОФА и УПА в лечении пациентов с ПсА, резистентных к синтетическим БПВП и ингибиторам фактора некроза опухоли α . Полученные к настоящему времени сведения позволяют рекомендовать ингибиторы JAK в качестве нового патогенетически обоснованного подхода к терапии ПсА.

The article presents an analysis of literature data on the use of a new group of targeted synthetic disease-modifying antirheumatic drugs (DMARDs) Janus kinase (JAK) inhibitors – tofacitinib (TOFA) and upadacitinib (UPA) – in psoriatic arthritis (PsA). The results of randomized placebocontrolled clinical trials and long-term observational studies indicate the high efficacy and safety of using TOFA and UPA in the treatment of patients with PsA who are resistant to synthetic DMARDs and tumor necrosis factor-α inhibitors. The information obtained so far allows us to recommend JAK inhibitors as a new pathogenetic approach to the treatment of PsA.

псориатический артритингибиторы Янус-киназтофацитинибупадацитинибтаргетные синтетические базисные противовоспалительные препаратыpsoriatic arthritisJanus kinase inhibitorstofacitinibupadacitinibtargeted synthetic basic anti-inflammatory drugsСтатья подготовлена в рамках научной темы «Патогенетические особенности и персонифицированная терапия анкилозирующего спондилита и псориатического артрита» (АААА-А19-119021190147-6, 0514-2019-0009).The investigation has been conducted within scientific topic № АААА-А19-119021190147-6, 0514-2019-0009 «Pathogenetic features and personalized therapy of ankylosing spondylitis and psoriatic arthritis».ReferencesCoates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheum. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015 May 7;17:115. doi: 10.1186/s13075-015-0640-3.FitzGerald O, Haroon M, Giles JT, Winchester R. Concepts of pathogenesis in psoriatic arthritis: genotype determines clinical phenotype. Arthritis Res Ther. 2015 May 7;17:115. doi: 10.1186/s13075-015-0640-3.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-12. doi: 10.1136/annrheumdis-2020-217159.Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/ National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.Singh JA, Guyatt G, Ogdie A, et al. Special Article: 2018 American College of Rheumatology/ National Psoriasis Foundation Guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. Epub 2018 Nov 30.Корсакова ЮЛ, Коротаева ТВ. Современная фармакотерапия псориатического артрита. Научно-практическая ревматология. 2019;57(1):75-82.Korsakova YuL, Korotaeva TV. Modern pharmacotherapy of psoriatic arthritis. Nauchno-prakticheskaya revmatologiya. 2019;57(1):75-82. (In Russ.).Логинова EЮ, Коротаева TВ, Глухова СИ, Насонов ЕЛ. Длительность ремиссии и минимальной активности болезни после инициации и отмены генно-инженерных биологических препаратов у больных ранним псориатическим артритом (данные Общероссийского регистра псориатического артрита). Научно-практическая ревматология. 2019;57(5): 523-7.Loginova EYu, Korotaeva TV, Glukhova SI, Nasonov EL. Duration of remission and minimal activity of the disease after initiation and withdrawal of genetically engineered biological drugs in patients with early psoriatic arthritis (data from the All-Russian Register of Psoriatic Arthritis). Nauchno-prakticheskaya revmatologiya. 2019;57(5): 523-7. (In Russ.).Gossec L, McGonagle D, Korotaeva T, et al. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018 Jan;45(1):6-13. doi: 10.3899/jrheum.170449. Epub 2017 Nov 15.Gossec L, McGonagle D, Korotaeva T, et al. Minimal Disease Activity as a Treatment Target in Psoriatic Arthritis: A Review of the Literature. J Rheumatol. 2018 Jan;45(1):6-13. doi: 10.3899/jrheum.170449. Epub 2017 Nov 15.Насонов ЕЛ, Олюнин ЮА, Лила АМ. Ревматоидный артрит: проблемы ремисии и резистентности к терапии. Научно-практическая ревматология. 2018;56(3): 263-71.Nasonov EL, Olyunin YuA, Lila AM. Rheumatoid arthritis: problems of remission and resistance to therapy. Nauchno-prakticheskaya revmatologiya. 2018;56(3):263-71. (In Russ.).Perrotta FM, De Socio A, Scriffignano S, Lubrano E. From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications. Expert Rev Clin Immunol. 2018 Mar;14(3):207-13. doi: 10.1080/1744666X.2018.1429918. Epub 2018 Jan 25.Perrotta FM, De Socio A, Scriffignano S, Lubrano E. From clinical remission to residual disease activity in spondyloarthritis and its potential treatment implications. Expert Rev Clin Immunol. 2018 Mar;14(3):207-13. doi: 10.1080/1744666X.2018.1429918. Epub 2018 Jan 25.Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843-62. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.Schwartz DM, Kanno Y, Villarino A, et al. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017 Dec;16(12):843-62. doi: 10.1038/nrd.2017.201. Epub 2017 Nov 6.Насонов ЕЛ, Лила АМ. Ингибиторы Янус-киназ при иммуновоспалительных ревматических заболеваниях: новые возможности и перспективы. Научно-практическая ревматология. 2019;57(1):8-16.Nasonov EL, Lila AM. Janus kinase inhibitors in immuno-inflammatory rheumatic diseases: new opportunities and prospects. Nauchno-prakticheskaya revmatologiya. 2019; 57(1):8-16. (In Russ.).Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017 Mar 22;18(4):374-84. doi: 10.1038/ni.3691.Villarino AV, Kanno Y, O'Shea JJ. Mechanisms and consequences of Jak-STAT signaling in the immune system. Nat Immunol. 2017 Mar 22;18(4):374-84. doi: 10.1038/ni.3691.Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019 Jun 1;58(6):953-62. doi: 10.1093/rheumatology/key339.Choy EH. Clinical significance of Janus Kinase inhibitor selectivity. Rheumatology (Oxford). 2019 Jun 1;58(6):953-62. doi: 10.1093/rheumatology/key339.Насонов ЕЛ, Авдеева АС, Лила АМ. Эффективность и безопасность тофацитиниба при иммуновоспалительных ревматических заболеваниях (часть I). Научно-практическая ревматология. 2020;58(1):62-79.Nasonov EL, Avdeeva AS, Lila AM. Efficacy and safety of tofacitinib in immuno-inflammatory rheumatic diseases (Part I). Nauchnoprakticheskaya revmatologiya. 2020;58(1): 62-79. (In Russ.).Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018 Sep;14(9):719-30. doi: 10.1080/1744666X.2018.1512404.Berekmeri A, Mahmood F, Wittmann M, Helliwell P. Tofacitinib for the treatment of psoriasis and psoriatic arthritis. Expert Rev Clin Immunol. 2018 Sep;14(9):719-30. doi: 10.1080/1744666X.2018.1512404.Ly K, Beck KM, Smith MP, et al. Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl). 2019 Aug 28;9:97-107. doi: 10.2147/PTT.S161453.eCollection2019.Ly K, Beck KM, Smith MP, et al. Tofacitinib in the management of active psoriatic arthritis: patient selection and perspectives. Psoriasis (Auckl). 2019 Aug 28;9:97-107. doi: 10.2147/PTT.S161453.eCollection2019.Paik J, Deeks ED. Tofacitinib: A review in psoriatic arthritis. Drugs. 2019 Apr;79(6): 655-63. doi: 10.1007/s40265-019-01091-3.Paik J, Deeks ED. Tofacitinib: A review in psoriatic arthritis. Drugs. 2019 Apr;79(6): 655-63. doi: 10.1007/s40265-019-01091-3.Veale DJ, McGonagle D, McInnes IB, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019 Feb 1;58(2):197-205. doi: 10.1093/rheumatology/key070.Veale DJ, McGonagle D, McInnes IB, et al. The rationale for Janus kinase inhibitors for the treatment of spondyloarthritis. Rheumatology (Oxford). 2019 Feb 1;58(2):197-205. doi: 10.1093/rheumatology/key070.Van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Aug;76(8):1340-7. doi: 10.1136/annrheumdis-2016-210322. Epub 2017 Jan 27.Van der Heijde D, Deodhar A, Wei JC, et al. Tofacitinib in patients with ankylosing spondylitis: a phase II, 16-week, randomised, placebo-controlled, dose-ranging study. Ann Rheum Dis. 2017 Aug;76(8):1340-7. doi: 10.1136/annrheumdis-2016-210322. Epub 2017 Jan 27.Deodhar A, Chakravarty SD, Cameron C, et al. A systematic review and network metaanalysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. 2020 Aug;39(8):2307-2315. doi: 10.1007/s10067-020-04970-3. Epub 2020 Feb 27.Deodhar A, Chakravarty SD, Cameron C, et al. A systematic review and network metaanalysis of current and investigational treatments for active ankylosing spondylitis. Clin Rheumatol. 2020 Aug;39(8):2307-2315. doi: 10.1007/s10067-020-04970-3. Epub 2020 Feb 27.Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Apr 27;80(8):1004-13. doi: 10.1136/annrheumdis-2020-219601. Online ahead of print.Deodhar A, Sliwinska-Stanczyk P, Xu H, et al. Tofacitinib for the treatment of ankylosing spondylitis: a phase III, randomised, double-blind, placebo-controlled study. Ann Rheum Dis. 2021 Apr 27;80(8):1004-13. doi: 10.1136/annrheumdis-2020-219601. Online ahead of print.Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus Kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73. doi: 10.1124/dmd.113.054940. Epub 2014 Jan 24.Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a Janus Kinase inhibitor, in humans. Drug Metab Dispos. 2014 Apr;42(4):759-73. doi: 10.1124/dmd.113.054940. Epub 2014 Jan 24.Насонов ЕЛ, редактор. Ревматология. Российские клинические рекомендации. Москва: ГЭОТАР-Медиа; 2017. 456 с.Nasonov EL, editor. Revmatologiya. Rossiiskie klinicheskie rekomendatsii [Rheumatology. Russian clinical guidelines]. Moscow: GEOTAR-Media; 2017. 456 p..Mease P, Hall S, Fitzgerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017 Oct 19; 377(16):1537-50. doi: 10/1056/NEJMoa1615975.Mease P, Hall S, Fitzgerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017 Oct 19; 377(16):1537-50. doi: 10/1056/NEJMoa1615975.Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017 Oct 19;377(16): 1525-36. doi: 10.1056/NEJMoa1615977.Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017 Oct 19;377(16): 1525-36. doi: 10.1056/NEJMoa1615977.Nash P, Coates L, Fleischmann R, et al. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018 Dec; 5(2):567-82. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.Nash P, Coates L, Fleischmann R, et al. Efficacy of Tofacitinib for the Treatment of Psoriatic Arthritis: Pooled Analysis of Two Phase 3 Studies. Rheumatol Ther. 2018 Dec; 5(2):567-82. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.Helliwell P, Coates LC, FitzGerald O, et al. Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res. Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.Helliwell P, Coates LC, FitzGerald O, et al. Janus kinase inhibitor treatment that targets multiple domains of disease. Arthritis Res. Ther. 2018 Oct 29;20(1):242. doi: 10.1186/s13075-018-1739-0.Van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis patients treated with tofacitinib or adalimumab. J Rheumatol. 2019 Sep;46(9):1089-96. doi: 10.3899/jrheum.180971. Epub 2019 Mar 1.Van der Heijde D, Gladman DD, FitzGerald O, et al. Radiographic progression according to baseline C-reactive protein levels and other risk factors in psoriatic arthritis patients treated with tofacitinib or adalimumab. J Rheumatol. 2019 Sep;46(9):1089-96. doi: 10.3899/jrheum.180971. Epub 2019 Mar 1.Nash P, Coates LC, Fleischmann R, et al. Efficacy of Tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2018 Dec;5(2):567-82. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.Nash P, Coates LC, Fleischmann R, et al. Efficacy of Tofacitinib for the treatment of psoriatic arthritis: pooled analysis of two phase 3 studies. Rheumatol Ther. 2018 Dec;5(2):567-82. doi: 10.1007/s40744-018-0131-5. Epub 2018 Nov 9.Губарь ЕЕ, Корсакова ЮЛ, Логинова ЕЮ и др. Влияние терапии тофацитинибом на динамику активного сакроилиита у больных псориатическим артритом. Научно-практическая ревматология. 2021;59(2): 134-40.Gubar' EE, Korsakova YuL, Loginova EYu, et al. The effect of tofacitinib therapy on the dynamics of active sacroiliitis in patients with psoriatic arthritis. Nauchno-prakticheskaya revmatologiya. 2021;59(2):134-40. (In Russ.).Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from OPAL BALANCE, an open-label, long-term extension study. Ann Rheum Dis. 2017;76:682. doi: 10.1136/annrheumdis-2017-eular.1414.Nash P, Coates LC, Kivitz AJ, et al. Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, up to 24 months in patients with active psoriatic arthritis: interim data from OPAL BALANCE, an open-label, long-term extension study. Ann Rheum Dis. 2017;76:682. doi: 10.1136/annrheumdis-2017-eular.1414.Nash PCL, Kivitz AJ, Mease PJ, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the second interim analysis of OPAL balance, an open-label, long-term extension study [abstract]. https://acrabstracts.org/abstract/safety-and-efficacy-of-tofacitinib-an-oraljanus-kinase-inhibitor-up-to-36-months-inpatients-with-active-psoriatic-arthritis-datafrom-the-third-interim-analysis-of-opalbalance-an-open-label-lo/Nash PCL, Kivitz AJ, Mease PJ, et al. Safety and efficacy of tofacitinib, an oral Janus kinase inhibitor, up to 36 months in patients with active psoriatic arthritis: data from the second interim analysis of OPAL balance, an open-label, long-term extension study [abstract]. https://acrabstracts.org/abstract/safety-and-efficacy-of-tofacitinib-an-oraljanus-kinase-inhibitor-up-to-36-months-inpatients-with-active-psoriatic-arthritis-datafrom-the-third-interim-analysis-of-opalbalance-an-open-label-lo/Nash P, Coates L, Mease P, et al. Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebocontrolled Sub-study of OPAL Balance [abstract]. https://acrabstracts.org/abstract/tofacitinib-as-monotherapy-following-methotrexate-withdrawal-in-patientswith-psoriatic-arthritis-previously-treated-with-open-label-tofacitinib-methotrexate-a-randomized-placebo-controlled-sub-st/Nash P, Coates L, Mease P, et al. Tofacitinib as Monotherapy Following Methotrexate Withdrawal in Patients with Psoriatic Arthritis Previously Treated with Open-label Tofacitinib + Methotrexate: A Randomized, Placebocontrolled Sub-study of OPAL Balance [abstract]. https://acrabstracts.org/abstract/tofacitinib-as-monotherapy-following-methotrexate-withdrawal-in-patientswith-psoriatic-arthritis-previously-treated-with-open-label-tofacitinib-methotrexate-a-randomized-placebo-controlled-sub-st/Логинова ЕЮ, Корсакова ЮЛ, Губарь ЕЕ и др. Эффективность и безопасность тофацитиниба у больных псориатическим артритом в реальной клинической практике. Научно-практическая ревматология. 2020;58(3):268-75.Loginova EYu, Korsakova YuL, Gubar' EE, et al. Efficacy and safety of tofacitinib in patients with psoriatic arthritis in real clinical practice. Nauchno-prakticheskaya revmatologiya.2020;58(3):268-75. (In Russ.).Gratacos Masmitja J, Gonzalez Fernandez CM, Gomez Castro S, Rebollo Laserna FJ. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Adv Ther. 2021 Feb;38(2):868-84. doi: 10.1007/s12325-020-01585-7. Epub 2020 Dec 17.Gratacos Masmitja J, Gonzalez Fernandez CM, Gomez Castro S, Rebollo Laserna FJ. Efficacy of Tofacitinib in the Treatment of Psoriatic Arthritis: A Systematic Review. Adv Ther. 2021 Feb;38(2):868-84. doi: 10.1007/s12325-020-01585-7. Epub 2020 Dec 17.McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.McInnes IB, Byers NL, Higgs RE, et al. Comparison of baricitinib, upadacitinib, and tofacitinib mediated regulation of cytokine signaling in human leukocyte subpopulations. Arthritis Res Ther. 2019 Aug 2;21(1):183. doi: 10.1186/s13075-019-1964-1.Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019 Nov 15;7(6): e00537. doi: 10.1002/prp2.537.eCollection2019Dec.Dowty ME, Lin TH, Jesson MI, et al. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition. Pharmacol Res Perspect. 2019 Nov 15;7(6): e00537. doi: 10.1002/prp2.537.eCollection2019Dec.Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019 Jan;15(1):13-25. doi: 10.1080/1744666X.2019.1544892. Epub 2018 Nov 19.Serhal L, Edwards CJ. Upadacitinib for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol. 2019 Jan;15(1):13-25. doi: 10.1080/1744666X.2019.1544892. Epub 2018 Nov 19.Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020 Sep;30(5):779-87. doi: 10.1080/14397595.2020.1782049. Epub 2020 Jul 13.Tanaka Y. A review of upadacitinib in rheumatoid arthritis. Mod Rheumatol. 2020 Sep;30(5):779-87. doi: 10.1080/14397595.2020.1782049. Epub 2020 Jul 13.Насонов ЕЛ, Лила АМ. Перспективы применения упадацитиниба при ревматоидном артрите и других иммуновоспалительных ревматических заболеваниях. Научно-практическая ревматология. 2020;58(5):532-43.Nasonov EL, Lila AM. Prospects for the use of upadacitinib in rheumatoid arthritis and other immuno-inflammatory rheumatic diseases. Nauchno-prakticheskaya revmatologiya. 2020;58(5):532-43. (In Russ.).Mcinnes I, Anderson J, Magrey M, et al. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to nonbiologic disease-modifying anti-rheumatic drugs (SELECT-PsA-1): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:16-7. doi: 10.1136/annrheumdis-2020-eular.6727.Mcinnes I, Anderson J, Magrey M, et al. Efficacy and safety of upadacitinib versus placebo and adalimumab in patients with active psoriatic arthritis and inadequate response to nonbiologic disease-modifying anti-rheumatic drugs (SELECT-PsA-1): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:16-7. doi: 10.1136/annrheumdis-2020-eular.6727.Mcinnes I, Anderson J, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1; 384(13):1227-39. doi: 10.1056/NEJMoa2022516.Mcinnes I, Anderson J, Magrey M, et al. Trial of Upadacitinib and Adalimumab for Psoriatic Arthritis. N Engl J Med. 2021 Apr 1; 384(13):1227-39. doi: 10.1056/NEJMoa2022516.McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021 Oct; 7(3):e001838. doi: 10.1136/rmdopen-2021-001838.McInnes IB, Kato K, Magrey M, et al. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study. RMD Open. 2021 Oct; 7(3):e001838. doi: 10.1136/rmdopen-2021-001838.Genovese MC, Lertratanakul A, Anderson J, et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:139. doi: 10.1136/annrheumdis-2020-eular.1229.Genovese MC, Lertratanakul A, Anderson J, et al. Efficacy and safety of upadacitinib in patients with active psoriatic arthritis and inadequate response to biologic disease-modifying anti-rheumatic drugs (SELECT-PSA-2): a double-blind, randomized controlled phase 3 trial. Ann Rheum Dis. 2020;79:139. doi: 10.1136/annrheumdis-2020-eular.1229.Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020 Dec 3;80(3):312-20. doi: 10.1136/annrheumdis-2020-218870.Online ahead of print.Mease PJ, Lertratanakul A, Anderson JK, et al. Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2. Ann Rheum Dis. 2020 Dec 3;80(3):312-20. doi: 10.1136/annrheumdis-2020-218870.Online ahead of print.Deodhar А, Ranza R, Ganz F, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement. Ann Rheum Dis. 2021;80(Suppl 1):143-4. doi: 10.1136/annrheumdis-2021-eular.439.Deodhar А, Ranza R, Ganz F, et al. Efficacy and safety of upadacitinib in patients with psoriatic arthritis and axial involvement. Ann Rheum Dis. 2021;80(Suppl 1):143-4. doi: 10.1136/annrheumdis-2021-eular.439.Van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214): 2108-17. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.Van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019 Dec 7;394(10214): 2108-17. doi: 10.1016/S0140-6736(19)32534-6. Epub 2019 Nov 12.Nash P, Richette P, Gossec L, et al. Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials [abstract]. https://acrabstracts.org/abstract/upadacitinib-as-monotherapy-and-in-combinationwith-non-biologic-dmards-for-the-treaNash P, Richette P, Gossec L, et al. Upadacitinib as Monotherapy and in Combination with Non-biologic DMARDs for the Treatment of Psoriatic Arthritis: Subgroup Analysis from Two Phase 3 Trials [abstract]. https://acrabstracts.org/abstract/upadacitinib-as-monotherapy-and-in-combinationwith-non-biologic-dmards-for-the-trea

The authors declare that there are no conflicts of interest present.